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Abstract
Congenital heart disease (CHD) is an indication which spans multiple specialties 
across various genetic counseling practices. This practice resource aims to provide 
guidance on key considerations when approaching counseling for this particular indi-
cation while recognizing the rapidly changing landscape of knowledge within this do-
main. This resource was developed with consensus from a diverse group of certified 
genetic counselors utilizing literature relevant for CHD genetic counseling practice 
and is aimed at supporting genetic counselors who encounter this indication in their 
practice both pre- and postnatally.
K E Y W O R D S
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resource
1  | INTRODUC TION
Congenital heart disease/defects (CHD/CHDs) constitute a heter-
ogenous group of cardiovascular malformations and represent the 
most common birth defects in humans. These malformations have a 
birth incidence of 0.8%– 1%, with an estimated global prevalence of 
approximately 1%– 2% due to improved diagnosis, surgical interven-
tions, and survival in the last three decades (Pierpont et al., 2018). 
The prevalence of adults with CHDs is now greater than that of chil-
dren, with approximately 90% of individuals surviving into adulthood 
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(Mazor Dray & Marelli, 2015). Given this, we anticipate a greater 
need for genetic counselors, across several specialties, to be familiar 
with CHDs, as they may encounter this indication more frequently in 
both their patient population and/or while obtaining a family history.
The American Heart Association (AHA) and European Society 
of Cardiology (ESC) have recently highlighted the current under-
standing of the genetic underpinnings of CHDs and the utility of 
genetic counseling and genetic testing for the pediatric and adult 
CHD populations (Baumgartner et al., 2020; De Backer et al., 2019; 
Pierpont et al., 2018). Given the clinical and etiologic heterogeneity 
of CHDs, as well as the rapidly changing nature of diagnostic genetic 
testing options available, genetic counseling for this indication can 
be complex. Because of this recognized need, we aimed to create a 
resource that provides CHD- specific counseling strategies and ap-
proaches for genetic counselors of any experience level or specialty 
that is supported by narrative literature review. A group of genetic 
counselors representing multiple specialties with significant pro-
fessional experience counseling in the setting of CHDs convened in 
2019 and developed this resource over the course of approximately 
15 months (2019– 2020).
In this practice resource, we review topics that can assist with 
guiding CHD counseling strategies including cardiac development, 
genetic testing approaches, and strategies for recurrence risk coun-
seling and family risk assessment in syndromic and apparently iso-
lated CHDs. A broad overview of these strategies can be found in 
Table 1. We also review the benefits of caring for patients with CHD 
using a multidisciplinary team approach involving genetic counsel-
ors, medical geneticists, and cardiologists. Last, we briefly review 
resources for the unique setting of prenatal genetic counseling for 
CHDs. This resource assumes readers have some basic prior knowl-
edge of contemporary practice and genetic technologies (e.g., chro-
mosome microarray, next- generation sequencing, and noninvasive 
cell- free fetal DNA screening). This practice resource was developed 
to serve as a solid foundation for genetic counseling approaches to 
CHDs in an area that has been changing rapidly in the last decade, 
with advances in genetic and genomic testing technologies increas-
ing the understanding of the genetic basis of CHDs. As a brief note, 
the terms ‘congenital heart defect(s)’ and ‘congenital heart disease’ 
can be interchangeably used, and both are acceptable disease de-
scriptions with the same acronym (CHD).
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A basic understanding of cardiac embryogenesis can provide insight 
into the genetic etiology of CHDs. By common convention, the clas-
sification of CHDs is often centered on the physiological effects 
or outcomes such as cyanotic (lesions which decrease the amount 
of blood flow to the body, e.g., tetralogy of Fallot) and acyanotic 
CHDs. This classification scheme guides the surgical and medical 
TA B L E  1   Genetic counseling considerations for CHDs in different scenarios: CHDs with syndromic features vs. isolated CHDs (sporadic 
and familial)




Differential • Suspected underlying genetic 
syndrome (single gene or 
chromosomal)
• Single gene or chromosomal cause 
associated with isolated CHD
• Single gene or chromosomal cause 
associated with syndromic CHD and 
more mild presentation
• Multifactorial




• Guided by etiology of suspected 
syndrome
• Consideration of CMA as first- 
line test ± additional molecular 
genetic testing
• CMA
• Consider CHD Panel if CMA negative
• Consider ES/GS if CHD Panel negative 
and family is interested (with affected 
family members as part of a family 
analysis)
• CMA
• Consider CHD gene sequencing or panel 
based on lesion (e.g., ELN for SVAS)
Recurrence 
risk
• Based on inheritance of particular 
syndrome identified and if 
inherited from a parent
• If no diagnosis is made, 
counseling on recurrence risk is 
less specific
• Positive Testing: Based on inheritance 
pattern, reduced penetrance, and 
variable expressivity
• Negative Testing: Unable to provide 
exact recurrence risk but could be as 
high as 50%
• Positive Testing: Based on inheritance 
pattern, reduced penetrance, and 
variable expressivity
• Negative Testing: Refer to empiric data 
based on lesion type
Family 
screening
• Fetal echocardiography in future 
pregnancies is reasonable if 
pregnancy considered at- risk for 
syndrome
• Cardiac screening may be 
appropriate based for at- risk 
family members
• Fetal echocardiography in future at- 
risk pregnancies
• If LVOTO, cardiac screening for first- 
degree relatives
• Fetal echocardiography in future at- risk 
pregnancies
• If LVOTO, cardiac screening for first- 
degree relatives
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management decisions for patients with CHDs. While this classifi-
cation scheme is useful to cardiologists, surgeons, and other physi-
cians, a different classification system that centers on the underlying 
developmental processes is often more useful from the perspective 
of clinical genetics and genetic counseling.
The dynamic process of cardiac development requires numerous 
sequential and time- sensitive steps within the first few weeks of 
embryogenesis. These steps are orchestrated by a complex genetic 
network of transcription factors, cell signalers, histone/chromatin 
modifiers (e.g., NKX2.5, JAG1, NOTCH1, GATA4, and CHD7), and, in 
some instances, sarcomeric and other structural- encoding proteins. 
Disruption of these genes can lead to different ‘categories’ of CHDs. 
For instance, NOTCH1 is more strongly associated with left ventric-
ular outflow tract defects (LVOTO), such as bicuspid aortic valve and 
coarctation of the aorta (Preuss et al., 2016).
In order to meet the challenge of categorizing cardiovascular 
malformations, the ‘Botto’ classification scheme categorizes CHDs 
reflective of development (for instance, whether a lesion is due to 
an aberration in conotruncal development vs. septal development) 
(Botto et al., 2007). The Botto criteria consider several higher- level 
categories for which varieties of simple and complex CHDs can be 
grouped (see Table 2). The advantage of this classification scheme is 
that knowledge of the cardiac malformation embryological stage is 
reflective of, to a degree, the underlying genetics of heart develop-
ment. Having a basic understanding of this process can assist with 
informing the selection of differential diagnoses for syndromic pre-
sentations and relevant genes to prioritize for analysis. See Table 3 
for a list of genes and genetic syndromes associated with the various 
Botto classes and Appendix S1 for examples of how to utilize the 
Botto classification scheme.
Level 3 class
Detailed cardiac phenotypes (Level 1) comprising the 
class
Anomalous pulmonary venous 
return (APVR)
TAPVR, PAPVR
Atrioventricular Septal Defect 
(AVSD)
Primum ASD, inlet VSD, complete AVSD/complete AV 
canal defect, AVSD +outflow tract obstruction
Complex Multiple complex heart anomalies, complex single 
ventricle defects, L- TGA (± LVOTO)
Conotruncal DORV, DORV- TOF type, DORV- TGA type, TA, IAA, IAA- 
B, D- TGA, D- TGA ± VSD or outflow tract obstruction, 
TOF
Heterotaxy Heterotaxya , situs inversus totalis/ambiguus ± CHD, 
dextrocardia, mesocardia, persistent L- SVC (i.e., 
bilateral SVC), interrupted IVC, asplenia/polysplenia 
+CHD, midline or left- sided liver +CHD, other 
gastrointestinal situs anomalies +CHD
Left Ventricular Outflow Tract 
Obstruction (LVOTO)
BAV, HLHS, AS (± CoA), CoA (± VSD), MA, Shone's 
complex
Right Ventricular Outflow Tract 
Obstruction (RVOTO)
PA (± VSD), PVS (± ASD or any noninlet VSD), Ebstein 
anomaly, tricuspid atresia
Septal VSD (nonspecific), VSD (perimembranous, muscular, or 
noninlet), secundum ASD, multiple co- occurring ASD 
or VSD
Note: Abbreviations: APVR, anomalous pulmonary venous return; AS, aortic stenosis; ASD, atrial 
septal defect; AVSD, atrioventricular septal defects (i.e., atrioventricular canal defects/AV canal 
defects); BAV, bicuspid aortic valve; CHD, congenital heart defect (not specified); CoA, coarctation 
of the aorta; DORV, double- outlet right ventricle; D- TGA, dextro- transposition of the great 
arteries; HLHS, hypoplastic left heart syndrome; IAA, interrupted aortic arch; IAA- B, interrupted 
aortic arch type B; IVC, inferior vena cava; L- SVC, left superior vena cava; LVOTO, left ventricular 
outflow tract obstruction; MA, mitral valve atresia; PA, pulmonary atresia; PA- IVS, pulmonary 
atresia with intact ventricular septum; PAPVR, partial anomalous pulmonary venous return; PVS, 
pulmonary valve stenosis; SVC, superior vena cava; TA, truncus arteriosus; TAPVR, total anomalous 
pulmonary venous return; TGA, transposition of the great arteries (not specified); TOF, tetralogy of 
Fallot; VSD, ventricular septal defect (not specified).
Examples provided are not fully inclusive, and genetic counselors should collaborate with 
cardiologists familiar with these criteria for accurate CHD phenotype classification, or to resolve 
classification uncertainty (Sources: Botto et al., 2007).
aThis category may also include laterality- spectrum disorder malformations, and examples that are 
more inclusive of these malformations are provided here compared to what was originally reported 
by Botto et al. (2007).
TA B L E  2   Embryological classification 
of CHDs using the Botto criteria
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3  | CONGENITAL HE ART DEFEC T 
ETIOLOGIES
3.1 | Genetic contribution to CHD
When thinking about the possible genetic etiologies of CHDs, it can 
be helpful to focus the approach on two categories: monogenic/
chromosomal vs. polygenic/multifactorial. Combining genetic test-
ing techniques, a monogenic or cytogenetic etiology can be deter-
mined in around 20%– 30% of cases, meaning that the underlying 
cause of the majority of individuals with CHDs (~60%– 70%) cur-
rently remains unclear (Blue et al., 2017; Cowan & Ware, 2015). 
In instances of isolated/sporadic CHD, Mendelian causes with a 
single locus and large effect is a less common cause and is sus-
pected to be more likely due to a complex aggregate of polygenic/
oligogenic loci with additive effects (Blue et al., 2017; Marian et al., 
2011). However, polygenic models for CHD etiology are still being 
explored. Even in instances of apparently autosomal dominant in-
heritance of CHDs within a family, identifying a monogenic cause 
has proven to be challenging, indicating there may be a stronger 
oligogenic component to isolated CHD (both sporadic and famil-
ial) (Reuter et al., 2020). In contrast, individuals with extracardiac 
anomalies and/or dysmorphic features are more likely to have a 
diagnostic finding with genetic testing, especially chromosomal 
abnormalities or single- gene Mendelian syndromes (Cowan & 
Ware, 2015; Jin et al., 2017). Because of this, patients should be 
assessed by a medical geneticist or experienced dysmorpholo-
gist, when possible, for subtle noncardiac malformations, dysmor-
phisms, and developmental differences that may represent a mild 
presentation of a genetic syndrome. This may ultimately alter ge-
netic testing strategies, anticipated yields of genetic testing, and 
recurrence/familial risk counseling. When an underlying genetic 
cause is identified, it is currently most commonly due to chromo-
somal copy- number variants, followed by aneuploidy, and finally, 
single- gene variants (Figure 1).
Studies have shown that de novo genetic variants in devel-
opmental genes critical for heart development may be more en-
riched in individuals with CHDs compared with unaffected controls 
(Pasipoularides, 2018; Zaidi et al., 2013). Additionally, studies have 
shown that de novo variants are more likely to be associated with 
syndromic CHD, while inherited protein- truncating variants may be 
more common for nonsyndromic CHDs (Jin et al., 2017; Paige et al., 
2018; Sifrim et al., 2016). Understanding the underlying genetic eti-
ology of CHDs is complex, and there is still much to be learned. With 
the increased implementation of exome and genome sequencing 
into clinical care, it is likely that our understanding of this topic will 
evolve over the years, shifting the counseling and testing strategy.
3.2 | Environmental causes
In addition to genetic causes, previous epidemiologic studies sug-
gest environmental causes could explain approximately 2% of 
CHDs, highlighting roles for environmental teratogenic risk fac-
tors in a subset of cases (Jenkins et al., 2007; Kučienė & Dulskienė, 
2008). These environmental exposures (i.e., any nongenetic risk fac-
tor affecting the fetal– placental– maternal environment) have been 
limited to those occurring in the periconceptional period. This pe-
riod has been defined as three months prior to conception extend-
ing through the first trimester of pregnancy, with special attention 
to the first 2– 6 weeks of gestation during critical cardiac develop-
mental stages (Patel & Burns, 2013). However, quantifying risk esti-
mates for cardiac teratogens has been difficult owing to challenges 
in teratology study design, recall bias by study participants, limited 
animal model studies, and the possibilities of confounding variables 
in many studies (Mahler & Butcher, 2011). Given the incomplete un-
derstanding of cardiac teratogens and difficulty in providing defini-
tive causal evidence supporting a single environmental risk factor's 
role in CHD occurrence, genetic counselors should exercise caution 
in excluding a genetic etiology, even when a teratogenic cause is 
plausible.
Obtaining information on the prenatal history and the possible 
presence of external risk factors can be valuable for the genetic 
counselor risk assessment and should be considered. Patel and 
Burns (2013) reviewed previous case– control studies assessing nu-
merous CHD- related teratogens with reported odds ratios. Across 
all CHDs, one of the strongest environmental risk factors was pre- 
gestational diabetes mellitus. Due to the dose- dependent relation-
ship between hemoglobin A1c and risk for fetal malformations, a 
high A1c level early in pregnancy would increase the concern for 
maternal diabetes as a contributor to the development of fetal CHDs 
(Helle & Priest, 2020; Nielsen et al., 2006; Wender- Ozegowska et al., 
2005). Additional environmental risk factors for CHD include, but 
are not limited to, first- trimester maternal rubella infection, mater-
nal phenylketonuria (hyperphenylalaninemia), exposure to particular 
classes of medications, and advanced maternal age given its associ-
ation with aneuploidy. Jenkins et al. (2007) also provide a compre-
hensive review of environmental and maternal health risk factors for 
fetal CHDs. See Figure 2 for additional environmental risk factors. 
Given this, we recommend assessing for the following prenatal his-
tory: dosage and timing of any maternal medication exposure, ma-
ternal A1c levels (both pre- pregnancy and during pregnancy), level 
of gestational or pre- gestational diabetes control in mothers with 
diabetes, and the timing and diagnosis (if known) of any maternal 
illness. See the recurrence risk section for additional details on how 
one might counsel in the presence of a possible environmental risk 
factor.
An in- depth review of various cardiac teratogens and their quan-
tified risks is beyond the scope of this work, and there are helpful 
peer- reviewed published resources for genetic counselors to con-
sider when further investigation of prenatal exposures is needed 
(Jenkins et al., 2007; Patel & Burns, 2013). Teratogen information da-
tabases such as Reprotox (https://www.repro tox.org/), Teris (https://
deohs.washi ngton.edu/teris/), and MotherToBaby (https://mothe 
rtoba by.org/) are helpful resources to use when determining the 
risks associated with a particular exposure.
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4  | TARGETED FAMILY HISTORY 
A SSESSMENT FOR CONGENITAL HE ART 
DISE A SE
When assessing a family history of CHDs, genetic counselors should 
be prepared to obtain additional details on this history with the 
understanding that CHDs are clinically and etiologically heteroge-
nous. If possible, it is recommended that a four- generation pedigree 
is obtained to try to capture a broad overview. Relevant informa-
tion to assess includes a) who else in the family has CHD(s) and 
how closely they are related to the proband (i.e., does this appear 
to be isolated or familial?), b) whether the affected individual has an 
underlying syndromic diagnosis or a presumed isolated defect, or 
whether other relatives have potentially syndromic features, and 
c) the findings of any previously performed genetic evaluation and 
genetic testing results (positive or negative). The purpose of obtain-
ing this information is to assist with gaining clearer insight into the 
possible etiology of CHD(s) in the proband and/or the family. To do 
this, it can be helpful to ask about when and how the individual was 
diagnosed, and whether the affected individual(s) had other con-
genital anomalies, and/or intellectual disability. Genetic counselors 
should keep in mind that due to variable expressivity and reduced 
penetrance, it may not always be clear if a CHD is truly isolated and/
or sporadic.
5  | GENETIC TESTING FOR CONGENITAL 
HE ART DEFEC TS
Given the variable genetic etiologies of CHDs (chromosome copy- 
number variation, aneuploidy, single- gene syndromes, single- gene 
nonsyndromic, etc.), there are a variety of genetic tests to consider 
in the genetic evaluation of CHD patients. This section aims to ex-
plore the utility of well- known testing modalities for individuals 
F I G U R E  1   Estimated prevalence of monogenic, cytogenetic, and complex/multifactorial CHD etiologies. The prevalence of chromosome 
copy- number variants is specified for both syndromic and apparently isolated CHDs. A range is provided for many of these etiologies 
with the darker shade indicating the lower end of the range and the lighter shade indicating the greater end of the range. Note: these 
categories collectively may not sum to 100% due to incomplete knowledge of multifactorial etiologies and because some CHD cases can 
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F I G U R E  2   Overview of common CHD teratogens and other environmental risk factors (Sources: Donofrio et al., 2014; Kalisch- Smith et 
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with CHDs as well as key considerations when determining testing 
strategies.
5.1 | Cytogenetic testing strategies
Chromosomal microarray analysis (CMA) is widely used as the 
initial genetic test for individuals with CHDs and is recommended 
as the first- tier test for individuals with congenital anomalies 
(Manning & Hudgins, 2010; Miller et al., 2010). With few excep-
tions (e.g., conotruncal anomalies and supravalvular aortic ste-
nosis), many guidelines do not directly address recommendations 
for use of CMA for individuals with apparently isolated CHD. 
However, institutions may perform, or at least offer, a CMA to all 
individuals with complex/critical CHD regardless of the presence 
or absence of recognized syndromic features. Though an individ-
ual may appear to have isolated CHD, genetic testing, particularly 
in the neonatal setting when additional extracardiac features may 
be mild and harder to identify, provides the opportunity to identify 
a genetic aberration which may have otherwise been missed and 
could impact clinical care and risk counseling. Overall, CMA has 
been found to currently have the greatest diagnostic yield across 
all testing modalities, identifying a diagnosis in 9%– 25% of individ-
uals with CHDs (Ahrens- Nicklas et al., 2016; Buckley et al., 2015; 
Geddes et al., 2019; Geng et al., 2014; Wang et al., 2018). The di-
agnostic yield of CMA is highest in those who have CHDs with ex-
tracardiac anomalies and/or neurodevelopmental disorders when 
compared to apparently isolated CHDs (15%– 25% and 4%– 17%, 
respectively) (Breckpot et al., 2010; Buckley et al., 2015; Geng 
et al., 2014; Turan et al., 2018; Wang et al., 2018). The yield and 
clinical utility of CMA for an older individual with CHD without 
extracardiac anomalies or developmental concerns remain to be 
explored (Ito et al., 2020). The European Society of Cardiology re-
cently published recommendations for how best to navigate test-
ing for this population of patients stating that there is currently no 
strong indication for CMA in the context of adult individuals with 
mild to moderately complex isolated CHD (De Backer et al., 2019). 
We encourage readers to review this resource when involved in 
the care of an adult individual with apparently isolated CHD (De 
Backer et al., 2019).
Researchers have examined whether the diagnostic yield of 
CMA differs based on the particular class of CHD. Some patterns 
have emerged (e.g., higher yields for conotruncal defects), leading 
the American Heart Association (AHA) to support CMA for any indi-
vidual with specific conotruncal anomalies including, but not limited 
to, interruption of the aortic arch type B, truncus arteriosus, and te-
tralogy of Fallot (Pierpont et al., 2018). More robust, lesion- specific 
data remain limited due to relatively small cohorts available (Buckley 
et al., 2015; Wang et al., 2018). Therefore, teams may consider a 
broader approach for using CMA in the assessment of CHD patients 
regardless of the underlying CHD class.
Historically, fluorescence in situ hybridization (FISH) was the 
standard test methodology for diagnosing recurrent microdeletions 
syndromes. While there are several proposed testing algorithms in 
the literature that include consideration of FISH with high suspicion 
for a specific CNV such as 22q11.2 deletion syndrome or Williams 
syndrome, multiple studies have demonstrated that starting with 
CMA is often more cost- effective and timely than performing 
FISH and/or karyotype then reflexing to CMA (Connor et al., 2014; 
Geddes et al., 2017). Karyotype and/or FISH are recommended with 
high suspicion for common aneuploidies like trisomy 13/18/21 and 
Turner syndrome and especially when there is a need to assess for 
chromosomal rearrangements that will guide recurrence risk coun-
seling (e.g., chromosomal translocations). The recent AHA Scientific 
Statement also suggests that it is reasonable to consider offering 
FISH to all individuals with supravalvular aortic stenosis (SVAS) given 
a strong association with William's syndrome (Pierpont et al., 2018).
5.2 | Single- Gene, Next- Generation Sequencing 
(NGS) panels, and exome/genome sequencing
As opposed to structural variants, single- gene variants currently ac-
count for a less significant proportion of CHDs with genetic test-
ing ranging from single- gene analysis to large multi- gene panels and 
exome/genome sequencing. Single- gene testing can be considered 
in specific cases based on cardiac lesion, presence or absence of ex-
tracardiac features, and family history of CHDs. For example, ELN 
single- gene analysis should be considered in an individual with iso-
lated SVAS with or without a family history of SVAS. In a study by 
Blue et al., (2014), the yield of ELN sequencing in individuals with 
SVAS was estimated at ~3.4%. Single- gene analysis could also be 
considered for patients with suspected syndromic CHDs at the 
discretion of a medical geneticist and/or based on dysmorphology 
evaluation by an experienced clinician. Examples of this may include 
CHD7 analysis for CHARGE syndrome, JAG1 testing for Alagille syn-
drome, and TBX5 analysis for Holt– Oram syndrome. However, these 
syndromes are individually rare, so the yield of single- gene testing 
approaches for CHDs will have decreased utility without a priori sus-
picion of a specific single- gene syndrome.
Targeted multi- gene panels commonly used for CHDs include 
RASopathy gene panels and heterotaxy gene panels. RASopathy 
gene panels should be considered in patients with features of 
Noonan- spectrum disorders, valvar pulmonic stenosis with another 
cardiovascular malformation, or valvar pulmonic stenosis with spe-
cific extracardiac features (Anderson et al., 2019). Heterotaxy pan-
els with the inclusion of primary ciliary dyskinesia genes should be 
considered in patients with complex cardiac defects such as unbal-
anced atrioventricular canal defects or malposed great vessels with 
or without additional left- right patterning abnormalities (Geddes 
et al., 2020; Pierpont et al., 2018).
Large multi- gene CHD panels including both syndromic and iso-
lated CHD genes can be considered in cases with a broad differential 
diagnosis or in cases of familial CHD. Some studies have reported a 
31%- 46% yield of molecular diagnosis using a 57- gene CHD panel in 
cases of familial CHD (Blue et al., 2014; Jia et al., 2015). However, 
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this is likely a higher yield than expected due to the strong famil-
ial pattern in these study cohorts and due to less stringent variant 
interpretation practices (Richards et al., 2015). Next- generation se-
quencing panels, which can vary greatly between laboratories, are 
not typically the clinical standard of care for isolated (nonfamilial) 
CHD, as the yield is low. Panel testing may have advantages in that 
there is assessment of a pre- specified group of both syndromic and 
nonsyndromic CHD genes and is arguably more cost- effective than 
single- gene approaches. However, studies in patient cohorts with 
more narrowly defined case definitions (e.g., isolated vs. syndromic, 
adult vs. pediatric, and/or familial vs. sporadic) would be needed to 
investigate the utility and diagnostic yield of CHD gene panels, espe-
cially for apparently isolated CHDs.
While exome and genome sequencing (ES and GS, respectively) 
is available clinically, at this time most centers do not routinely use 
exome or genome analysis for identification of underlying genetic 
etiology of isolated CHDs. However, it is suspected that over time 
these methodologies will be incorporated more regularly into clinical 
practice, especially in the presence of a strong family history of CHD. 
ES and GS are more frequently utilized in research studies in search 
of novel genes, novel structural variants, and additional variant 
types which are unable to be detected by standard sequencing (such 
as deep intronic/splice- site variants). An example of such discover-
ies using ES was recently published in a study by Jin et al., (2017). 
Findings included discovery of a recessive Ashkenazi Jewish founder 
variant in GDF1, possible association between FTL4 loss- of- function 
variants with tetralogy of Fallot, and 12 additional novel genes with 
possible associations with CHDs. To date, the reported yield of ES 
and GS for CHDs has ranged widely in the literature due to vari-
ability in study design, case classifications, sample sizes, and variant 
interpretation stringency. Based on current literature, the diagnostic 
yield has been reported to range from 5 to 35+%, with generally 
higher yields for those with apparently syndromic CHDs (presence 
of extracardiac anomalies) (Blue et al., 2015; Homsy et al., 2015; Liu 
et al., 2020; Reuter et al., 2020; Sun et al., 2019; Szot et al., 2018; 
Zaidi et al., 2013). As with any use of ES, teams should be aware 
of the limitations of ES- based approaches, especially with variable/
reduced exon coverage for certain genes and decreased ability for 
identifying types of genomic variants like copy- number variants, 
genes in highly repetitive genomic regions, or genes with multi- 
nucleotide repeats. These limitations may be largely addressed by 
oncoming adoption of GS- based testing approaches within the next 
few years.
Last, some institutions may utilize exome- based gene panel anal-
ysis strategies that involve analysis of the exome but only provide 
interpretation of variants in genes associated with CHDs. This test-
ing approach can be beneficial for a more comprehensive analysis 
while minimizing the reporting of secondary findings or variants of 
unclear significance (VUS) in noncardiac genes. The ability to inter-
pret variants found in genes with possible but low evidence sup-
porting disease association complicates the use of broader genetic 
testing technologies. Some groups have also been able to identify 
chromosome copy- number variants from ES and GS data, and with 
improved bioinformatics approaches for these genomic variants, ES 
and GS may supplant CMA for copy- number variant identification in 
the future (e.g., Shi et al., 2018).
5.3 | Genetic testing and counseling considerations
Identifying a genetic etiology of a patient's CHD may offer benefits 
to the patient and family. Genetic testing may diagnose a disorder 
with established medical management guidelines or may influence 
pre- surgical laboratory evaluations (e.g., 22q11.2 deletion syndrome 
and immune system studies, Noonan syndrome and need for coagu-
lopathy workup) and medical care through the surgical process (e.g., 
William's syndrome and the increased risk of anesthesia complica-
tions) (Latham et al., 2016; Nugent et al., 2018). Even if a genetic 
diagnosis has no associated guidelines, medical management may 
be impacted. Multiple retrospective studies of patients undergoing 
CMA for any indication, including CHDs, have found that positive 
test results often warranted a referral to a subspecialist for surveil-
lance and/or intervention for a previously unrecognized disease 
(Ellison et al., 2012; Hayeems et al., 2015; Henderson et al., 2014). 
Data also show that individuals, including those with CHDs, found 
to carry a copy- number variant were more likely to have increased 
health challenges such as decreased transplant- free survival and 
poor growth (Carey et al., 2013; Kim et al., 2016). Additionally, some 
disorders may have long- term implications beyond CHDs, including 
increased risk for arrhythmias. This is the case for TBX5, which has 
been associated with both Holt– Oram syndrome (CHDs and limb 
digit anomalies) and apparently isolated CHDs. In both cases, there 
is an increased risk to develop arrhythmias requiring long- term heart 
rhythm surveillance and risk counseling. A similar risk of arrhythmias 
is seen in people with pathogenic NKX2- 5 variants.
During pretest counseling, the genetic counselor should discuss 
the possible results of genetic testing including pathogenic copy 
number variants and/or VUSs. This also includes those that have 
variable or uncertain phenotypes and the potential difficulty in pre-
dicting outcomes. This may be particularly relevant as CMA testing 
becomes more routinely used for individuals with isolated CHD 
without established syndrome- specific guidelines. An example of 
this can be seen with deletions of the 1q21.1 region that are known 
to have wide clinical variability and may demonstrate incomplete 
penetrance (Brunetti- Pierri et al., 2008). If a CHD panel is offered 
to an individual with isolated CHD, even in cases in which there is a 
strong family history, careful counseling is recommended to set ex-
pectations around a likely lower diagnostic yield and a greater VUS 
rate.
In summary, several variables must be considered when choos-
ing an appropriate genetic testing strategy. Multiple algorithms have 
been published providing suggested approaches to genetic testing for 
congenital heart disease (De Backer et al., 2019; Jerves et al., 2020; 
Zaidi & Brueckner, 2017). These algorithms provide similar guidance 
on the approach to testing in the instance of high suspicion for an-
euploidy or 22q11.2 deletion syndrome, with use of karyotype or 
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FISH/CMA, respectively. For patients with syndromic presentations, 
the algorithms similarly suggest starting with either targeted testing 
when a specific disorder is highly suspected, or CMA with a broader 
differential (or after an uninformative targeted test result) and con-
sideration of ES if initial testing is uninformative. For apparently non-
syndromic presentations, the proposed genetic testing strategies 
account for family history, CHD class, and reproductive age/decision 
making, with some variation among the algorithms. Two algorithms 
also note consideration of use of GS for research purposes when 
an alternative cause has not been identified (De Backer et al., 2019; 
Jerves et al., 2020). While these algorithms can help in the devel-
opment of testing protocols, institution- specific policies, procedures, 
and urgency of a clinical situation can affect genetic testing decisions.
6  | COUNSELING FOR CHD RECURRENCE 
RISK
Perhaps one of the most pertinent aspects of genetic counseling in-
volves the discussion of recurrence risk. This risk is dependent on 
many factors, including the presence or absence of an identifiable 
genetic etiology, known environmental or teratogenic exposures, 
family history, and CHD class (see discussion above regarding the 
Botto classification scheme).
6.1 | In the presence of a genetic etiology
Individuals with CHDs co- occurring with other congenital anoma-
lies, dysmorphic features, and/or developmental delays should be 
recommended for a formal genetics evaluation prior to estimating 
recurrence risk. If the CHD is explained by the identification of a 
Mendelian genetic syndrome, genetic counseling should proceed ac-
cording to the inheritance of that particular syndrome and whether 
the variant was inherited or de novo.
If a monogenic cause of isolated CHD is identified and there is 
substantial evidence supporting the pathogenicity of the causative 
variant, reduced penetrance and variable expressivity should be em-
phasized to patients/families when appropriate, and when discussing 
the risk to family members. An example of this concept is highlighted 
in a recent study of familial CHD caused by NOTCH1 variants, which 
demonstrated that penetrance was up to 75% for pathogenic variant 
carriers (Kerstjens- Frederikse et al., 2016). Similarly, incomplete pene-
trance was demonstrated in families with tetralogy of Fallot associated 
with FLT4 gene variants (Reuter et al., 2019). However, most gene vari-
ants associated with nonsyndromic, isolated CHD do not have pub-
lished penetrance information; therefore, it is reasonable to discuss 
the risk of an individual inheriting the variant (i.e., 50% risk to future 
children), but that the risk of CHD occurrence, as well as type/sever-
ity of CHD, may be less clear. As genotype– phenotype correlations 
improve, variant- specific risks will hopefully become available, allow-
ing the risk assessment to be more tailored. However, the research 
required to demonstrate gene- and variant- specific estimates of pen-
etrance and fuller ranges of expressivity will be substantial.
Some monogenic causes of CHD can be associated with an in-
creased risk of developing other cardiac phenotypes such as ar-
rhythmias and cardiomyopathies. These include, but are not limited 
to, MYH7, which can be associated with cardiomyopathy (Postma 
et al., 2011; Van der Linde et al., 2017), and GATA4, which has been 
associated with atrial fibrillation (Posch et al., 2010; Yang et al., 2011). 
In these cases, it is important to offer predictive testing to at- risk indi-
viduals, emphasize the risk to other family members, and highlight the 
variable features that may present in the family. It is also appropriate 
to counsel families that the risk of CHDs to individuals without the 
familial pathogenic variant is likely reduced to baseline risk.
Of note, in some cases, genes previously associated with genetic 
syndromes can cause apparently isolated CHD, further expanding 
our understanding of variable expressivity. For example, TBX5 has 
been associated with nonsyndromic CHDs, Holt– Oram syndrome, 
and dilated cardiomyopathy, demonstrating the spectrum of phe-
notypes associated with this gene (Zhou et al., 2015). In other in-
stances, identifying a variant in one of these genes may actually 
uncover an undiagnosed syndrome in the family that has thus far 
affected individuals relatively mildly (Blue et al., 2014).
Regardless of whether a pathogenic monogenic cause has been 
identified, the lines between Mendelian and complex multifactorial 
causes of CHDs are becoming increasingly blurred. This is especially 
salient when considering the complex interactions between cardiac 
developmental genes and their dependent activities in developmen-
tal gene networks (Waldron et al., 2016). It is likely that the under-
lying genetic complexities of CHDs drive the clinical and familial 
manifestations of incomplete penetrance and variable expressivity. 
In a study by Blue et al., (2017), individuals with CHDs, both in famil-
ial and in isolated cases, had a higher burden of variants in cardiac 
developmental genes than those without CHDs. Even in seemingly 
monogenic cases, there is likely an element of complex genetic or 
multifactorial contribution to the development of heart disease and 
related manifestations (e.g., cardiomyopathy and arrhythmias).
6.2 | In the absence of a known genetic etiology
In the absence of an identifiable genetic etiology or an uncertain 
genetic finding, the recurrence risk for isolated (apparently nonsyn-
dromic) congenital heart disease has been estimated from several 
large population studies. A summary of recurrence risk by CHD class 
has been reported by Cowan and Ware (2015) and can be used as a 
‘baseline’ risk. This risk can be modified (i.e., increased or lowered) 
by clinical observations such as a family history of CHDs and con-
firmed teratogenic exposures during pregnancy (e.g., limited control 
of maternal diabetes). When counseling a family concerned about 
recurrence, it is important to highlight the limitations of empiric 
risk calculations as they are based on population averages without 
knowledge of the actual underlying etiology.
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6.3 | Familial recurrences
The presence of more than one CHD within a family can increase 
risk of recurrence. As noted by population data, recurrence risk for 
any CHD is considered 2%– 3% for a family with one affected child 
and may increase to up to 50% with more than two affected first- 
degree relatives (Harper, 2010). However, even in a family history 
that appears to follow a Mendelian pattern of inheritance, reduced 
penetrance, often speculated to be associated with an oligogenic 
or multifactorial etiology, complicates estimation of the recurrence 
risk. Thus, when there is a strong family history of isolated CHD(s) 
that appears to follow an autosomal dominant inheritance pattern, 
and no genetic cause has been identified, one could consider coun-
seling that the risk to future offspring could potentially be up to 50%, 
but that it is also possible that this risk could be lower.
6.4 | CHD class
In the case of CHDs that are not suspected by the clinical team to be 
syndromic, lesion type can significantly affect the likelihood of recur-
rence (Figure 3). While there are studies suggesting increased risk of 
recurrence for almost any lesion type, left ventricular outflow tract 
lesions (LVOTO) have the highest recurrence risk of CHD classes. 
Common LVOTO lesions include hypoplastic left heart syndrome, 
aortic stenosis, coarctation of the aorta, or bicuspid aortic valve. It 
is important to note that an incidence of recurrence may not be of 
the same lesion and may be of varying severity such that occurrence 
of aortic stenosis, coarctation, and bicuspid aortic valve can all be 
noted within one family. Many publications have cited this in the 
case of HLHS where recurrence in siblings was lower for HLHS (0%– 
8%) but higher for other defects (13%– 31%)(Cowan & Ware, 2015; 
Kelle et al., 2015; Loffredo et al., 2004). Despite higher heritability 
of LVOTO CHDs, this does not necessarily mean that there will be a 
higher diagnostic yield of genetic testing or that other CHD classes 
do not have genetic contributions to their causes. It is still important 
to remember that all classes of CHDs likely have genetic causes, even 
if the LVOTO class is considered to have the highest heritability. This 
was explored by Øyen et al. (2009), reporting on the relative risk for 
all types of CHDs in individuals that had a first- degree relative with a 
CHD. Relative risks were substantial, ranging from ~3.0 to 79.0, and 
the overall relative risk for first- degree relatives to have the same or 
similar CHDs was ~8.0 to 12.0. Results from that study are difficult to 
use for genetic counseling practice because the relative risks in Øyen 
et al. (2009) do not translate easily to absolute recurrence risks (%).
6.5 | Environmental exposures
Finally, estimation of recurrence risk is not complete without a de-
tailed review of environmental exposures during pregnancy (as noted 
in the genetic etiology section above). Well- known exposures such as 
maternal diseases or teratogen exposures that reoccur during a sub-
sequent pregnancy can significantly increase one's risk for recurrence. 
F I G U R E  3   Schematic representing baseline recurrence risk for future children (based on empiric data), for apparently isolated CHD. Of 
note it is important to consider that this risk can be further modified by taking into consideration other risk factors such as the presence of 
maternal illness (ex. uncontrolled diabetes), teratogen exposure, and family history of CHD (especially if a parent or siblings is also affected 
by CHD – risk could be up to 50%) (Sources: Cowan & Ware, 2015; Freeze et al., 2016; Hales & Mahle, 2014). Abbreviations: AS, Aortic 
stenosis; BAV, Bicuspid aortic valve; CoA, Coarctation of the aorta; HLHS, Hypoplastic left heart; LVOTO, Left ventricular outflow tract 
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For instance, if a mother was known to have limited diabetes control 
during the pregnancy, this may decrease the concern for an underly-
ing genetic etiology and may indicate a lower recurrence risk, unless 
the mother were to similarly have limited control during a subsequent 
pregnancy. This same approach can be applied to other types of envi-
ronmental or maternal health teratogenic risk factors.
7  | CHD FAMILY SCREENING 
RECOMMENDATIONS
In the absence of an identified genetic risk factor, cardiac screening 
recommendations for family members of an affected individual var-
ies based on CHD class (e.g., LVOTO vs. non- LVOTO), family history, 
and practices of the specific center (Figure 4).
7.1 | LVOTO
As stated previously, left ventricular outflow tract obstruction 
(LVOTO) malformations are known to demonstrate one of the 
greatest heritability risks compared with other cardiac malforma-
tions. Currently, few professional organizations have published 
screening recommendations for first- degree family members of 
individuals with CHDs, with the exception of Hiratzka et al. (2010). 
These guidelines recommend that all first- degree relatives of an in-
dividual with a bicuspid aortic valve undergo a screening echocar-
diogram; it does not address cardiac screening for relatives of 
individuals with other LVOTO malformations. However, due to the 
body of literature documenting the increased incidence of CHDs in 
relatives with various LVOTOs, many centers recommend a base-
line screening echocardiogram for any first- degree relatives of an 
individual with any LVOTO (Demir et al., 2013; Hinton et al., 2007; 
Kelle et al., 2015; Kerstjens- Frederikse et al., 2011; McBride 
et al., 2005).
7.2 | Non- LVOTO screening considerations
For all other isolated cardiac lesions, there is a lack of formal guid-
ance for clinical screening of seemingly unaffected family members. 
This is true for scenarios where there is a clear familial inheritance 
F I G U R E  4   Family screening recommendations for individuals with isolated CHD for which the underlying genetic cause is unknown 
categorized by LVOTO and Non- LVOTO lesions. When screening for CHDs, generally it is recommended to have a single echocardiogram to 
confirm or exclude CHD. Generally, ongoing cardiac surveillance is not recommended if a previous echocardiogram was normal, unless there 
is indication to screen for other cardiac disease (i.e., cardiomyopathy). Abbreviations: BAV, Bicuspid aortic valve; CoA, Coarctation of the 
aorta; FDR, first- degree relative; HLHS, Hypoplastic left heart; LVOTO, Left ventricular outflow tract obstruction; Non- LVOTO, None Left 
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due to a high incidence of CHDs within a family. Whether or not a 
seemingly unaffected family member should undergo echocardiog-
raphy in these circumstances is primarily up to clinical judgment and/
or familial concern or interest.
As discussed previously, some monogenic causes of CHDs can 
be associated with an increased risk of developing other cardiac phe-
notypes such as arrhythmias and cardiomyopathies. It is important 
to keep in mind that variants associated with both CHD and car-
diomyopathy/arrhythmia can present with variable expression. For 
example, due to variable expressivity, individuals with pathogenic 
variants in ACTC1 can present with ASDs as well as HCM, DCM, or 
LVNC. Therefore, it is possible for one individual in the family to be 
born with a CHD, and another to only present with cardiomyopathy 
and/or arrhythmia. If a family has a pathogenic variant in a gene that 
can cause additional cardiac phenotypes, predictive testing is rec-
ommended for all first- degree family members, and cardiac screen-
ing (e.g., echocardiogram and ECG) would be indicated for relatives 
who are found to carry the variant, even if they are seemingly unaf-
fected, given that cardiomyopathy and arrhythmia can develop over 
time. It is also important that families understand that in these cases, 
a singular instance of cardiac screening may not be not sufficient to 
rule out disease, and ongoing cardiac screening may be necessary 
to monitor for the development of cardiomyopathy and arrhythmia 
over time.
8  | CHD MULTIDISCIPLINARY TE AM 
APPROACHES
Multiple professional organizations including the AHA and ESC 
stress the importance of a multidisciplinary approach to delivery 
of care for individuals with CHDs, inclusive of a genetic counselor 
and/or clinical geneticist (De Backer et al., 2019; Stout et al., 2019). 
However, there are limited data on the efficacy of different car-
diogenetics clinic models. Individuals and families with CHDs have 
identified genetic counselors and cardiologists as primary sources 
for genetic information (Van Engelen et al., 2011; Kasparian et al., 
,2014, 2018; Shikany et al., 2019). In one study, 93% of parents of 
children with CHDs reported being most likely to attend a cardio-
genetics clinical visit if there would be access to a geneticist and 
genetic counselor and in a timely manner (Kasparian et al., 2014).
Many individuals with CHDs are referred directly to a genetics 
clinic with a geneticist and genetic counselor, particularly in the 
presence of extracardiac anomalies. Studies have demonstrated 
improvement in diagnostic rate, appropriate management, and uti-
lization of genetic testing when a geneticist is involved in care of 
individuals with CHDs in various clinical settings (Van Engelen 
et al., 2013; Goldenberg et al., 2017). Given that neonates may pres-
ent with mild dysmorphic features that could go unnoticed and the 
inability to assess for developmental delays/learning disabilities at 
this stage in life, the geneticist can play a vital role in identification of 
subtle findings that may alter the differential and/or testing strategy.
Genetic counselors can add value to patient care by providing 
psychosocial support to families and education on the genetics of 
CHD, discussing cardiac screening recommendations for at- risk 
family members, providing information regarding recurrence risk 
estimates, interpreting genetic testing results, and performing 
predictive testing in the family when appropriate (Van Engelen 
et al., 2013). Dependent on institutional referral practices, a possible 
weakness of a cardiologist/genetic counselor- only model includes 
the exclusion of a dysmorphology evaluation. This can be especially 
important when genetic testing in an apparently nonsyndromic CHD 
case yields a variant in a gene that can have syndromic (i.e., extra-
cardiac) features.
As genetic risk assessment in CHDs is often lesion- specific, 
close collaboration between experienced cardiology clinicians 
F I G U R E  5   The multidisciplinary 
approach to CHD care and roles of the 
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can improve CHD classification and downstream risk assessment. 
For instance, close collaboration with a cardiologist may improve 
the separation of health outcomes that may be secondary to a pa-
tient's cardiac history (e.g., developmental delay due to the car-
diac surgical intervention) as opposed to an independent primary 
diagnosis. Some multidisciplinary clinics may allow for both a ge-
neticist and genetic counselor to work directly with cardiologists, 
while in other instances a genetic counselor may see patients with 
a cardiologist independent of a geneticist. With this approach, 
cardiologists and genetic counselors are encouraged to develop 
standard approaches for genetic testing and referring patients to 
a geneticist for syndromic evaluation, if indicated. In summary, 
cardiogenetics services can be diverse, consist of many models, 
and may employ a combination of genetic counselors, geneticists, 
and cardiologists dependent on institutional resources and pref-
erences (Figure 5). It is important to consider the advantages and 
disadvantages of each model given referral patterns and provider 
utilization that often will differ between institutions, and to de-
termine whether there are ways to supplement for resources that 
may not be available at one's institution. Last, a largely unexplored 
area includes multidisciplinary practice models targeted to adult 
CHD populations.
9  | CONSIDER ATIONS FOR PRENATAL 
GENETIC COUNSELING
9.1 | Counseling on a Family History of CHD(s)
In the prenatal genetic counseling setting, it is common to identify 
a history of CHDs in a parent of the fetus, prior child, or other fam-
ily member(s). The goal of the genetic counselor in these cases is to 
obtain as much detail as possible about the reported family history 
(e.g., relationship of affected relatives, type of CHD, and etiology if 
known) to inform risk assessment and offer testing options for the 
current pregnancy. See ‘the Targeted Family History’ section above 
for additional details on assessing for a family history of CHD.
Recurrence risk counseling is complicated by the fact that many 
prenatal patients do not know the underlying diagnosis in their af-
fected relative. The same recurrence risk principles reviewed above 
apply in the prenatal setting. A referral for genetic evaluation and test-
ing may be reasonable for the affected individual to help clarify specific 
risks However, further evaluation and testing of relatives may not be 
a viable option within the time- sensitive window to facilitate prenatal 
testing or accurate recurrence risk provision for the current pregnancy.
In the case where a pregnant mother has a personal history of 
apparently nonsyndromic CHD, she should be referred to adult con-
genital cardiology and high- risk obstetrics specialists with expertise 
in caring for such high- risk pregnancies with appropriate maternal 
surveillance. CHD class- specific recurrence risk counseling, as out-
lined previously, is important. If a genetic syndrome is suspected in 
the mother, evaluation by a medical geneticist may be helpful.
Fetal echocardiogram should be considered in pregnancies 
where the fetus has a close relative with CHD or a Mendelian disor-
der associated with CHD. A suspected structural, chromosomal, or 
heart rate/rhythm abnormality in the fetus would also warrant fetal 
echocardiogram, among other indications (Donofrio et al., 2014; Lee 
et al., 2020). Table 4 lists common indications for which fetal echo-
cardiogram is appropriate. Patients should be informed that certain 
types of CHDs may not be reliably detected even with fetal echocar-
diography and that postnatal echocardiography may be important.
Upon identifying a family history of a CHD, prenatal genetic 
counselors also have a unique opportunity to discuss the potential 
benefits of echocardiography screening for their pregnant patients 
and partners who may benefit from imaging themselves if their fam-
ily history meets the recommendations outlined above.
9.2 | Counseling on a fetus with a CHD 
identified prenatally
When a CHD is present in a fetus, prenatal identification can allow 
for the most appropriate management, for example, planning for de-
livery at a tertiary care facility with specialized neonatal and surgical 
care which can maximize outcomes for the fetus and the family.
One of the main challenges when counseling about a fetus with 
a CHD is that some lesions may be difficult to diagnose or specif-
ically characterize with a fetal echocardiogram or limitations of 
prenatal ultrasound. When a CHD is detected, a careful search for 
other malformations is important. Prenatal genetic counselors rely 
on the expertise of perinatology and pediatric cardiology special-
ists to determine the likely diagnosis, understanding that postnatal 
evaluation may provide additional information regarding the nature 
of the specific cardiac lesion or, more rarely, be normal. The family 
should be counseled that a diagnosis may change after delivery, ad-
ditional findings may be identified, and a referral to a geneticist may 
be a necessary part of postnatal care. As discussed previously (see 
TA B L E  4   Indications for fetal echocardiogram that may be 
pertinent for the prenatal genetic counseling setting
1st or 2nd degree relative of the fetus with CHD
1st or 2nd degree relative of fetus with Mendelian disorder that has 
CHD association
Fetal chromosome abnormality by diagnostic testing or cell- free 
DNA screening
Fetal cardiac abnormality suspected on ultrasound
Major fetal extracardiac abnormality suspected on ultrasound
Hydrops fetalis
Fetal increased NT >95% (≥3 mm)
Abnormal fetal heart rate or rhythm suspected on ultrasound
Pregnancy achieved via IVF
Monochorionic twins
High- risk maternal medical conditions, medication exposures, or 
infections
Note: (Sources: Donofrio et al., 2014; Lee et al., 2020).
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Etiology/Genetic Testing sections above), the genetic etiologies of 
CHDs are heterogeneous. Petracchi et al., (2019) provide a compre-
hensive overview of the most common genetic causes of fetal CHD 
tailored for prenatal providers.
Chromosome abnormalities are a major cause of fetal CHDs, 
even more prevalent than in newborns due to spontaneous loss of 
pregnancies with chromosomal abnormalities. Published literature 
can be utilized to provide data on the chance of a chromosome ab-
normality based on the specific cardiac lesion and presence of other 
anomalies. For example, a 2018 prospective cohort study of 602 
prenatal cases of fetal heart defects identified a pathogenic chro-
mosomal abnormality in 20.8% of cases, with 52% of them being 
due to aneuploidy and the remainder being copy- number variants 
(Wang et al., 2018). The detection rate of a pathogenic chromosomal 
abnormality was lower in cases of an isolated congenital heart de-
fect (14.3%) and increased in the presence of additional structural 
anomalies (48.9%) or intrauterine growth restriction (50.0%).
Studies of ES in the prenatal setting are emerging (Lord 
et al.,2019; Petrovski et al.,l., 2019; Westphal et al., 2019). In a recent 
study published in 2020, CMA and ES were performed sequentially 
in 360 fetuses with CHDs. A genetic diagnosis was encountered in 
84 cases (23.3%), with chromosomal abnormalities in 60 (16.7%) 
and sequence variants in 24 (6.7%). Of the 300 fetuses with normal 
CMA, 24 (8%) had a pathogenic/likely pathogenic variant identified 
through ES. Although aneuploidies were more frequent in fetuses 
with nonisolated CHDs, the frequency of copy number variants and 
sequence variants was not significantly different among fetuses with 
isolated vs. nonisolated CHDs. The authors of this study conclude 
that ES should be offered prenatally in all cases of CHDs with normal 
CMA results (Qiao et al., 2020).
9.3 | Prenatal genetic testing and additional 
considerations
In the setting of a fetus with CHD, patients should be offered both 
diagnostic testing and screening options. The American College 
of Obstetricians and Gynecologists (ACOG) issued a statement in 
December 2016 recommending CMA for patients with a fetus with 
one or more major structural abnormalities identified on ultrasound 
who are undergoing invasive prenatal diagnosis (Committee on 
Genetics & the Society for Maternal- Fetal Medicine, 2016). There 
have been numerous studies that demonstrate the utility of CMA 
as a first- tier test for a fetus with a CHD (Jansen et al., 2015; Turan 
et al., 2018; Wang et al., 2018).
Additional testing may be considered if CMA is normal such as a 
multi- gene panel or ES— especially if there are additional ultrasound 
findings suggestive of a genetic syndrome (e.g., extracardiac anom-
alies, growth restriction). See Appendix S2 for details on supporting 
guidelines for gene panels and ES.
Currently, ES in the prenatal setting is limited by turnaround 
time, cost, and insurance coverage. Additionally, interpretation of 
secondary findings or VUS can be particularly challenging in the 
prenatal setting where clinical information is limited and the impli-
cations for pregnancy management, including termination of preg-
nancy, are significant.
Last, with ongoing developments in cell- free fetal DNA (cfDNA) 
screening, there may be options for screening fetuses with CHDs 
for common aneuploidies via this modality (Gregg et al., 2016; 
Committee opinion no. 640, 2015). However, it is important to dis-
cuss the limitations of cfDNA analysis, emphasizing it is not a re-
placement for diagnostic testing. Cell- free DNA screening for select 
microdeletion syndromes (e.g., 22q11.2 deletion syndrome), certain 
single- gene disorders and genome- wide copy- number variants are 
also now available through several laboratories. Preliminary studies 
have suggested increased rates of cfDNA- positive results in fetuses 
with ultrasound abnormalities using genome- wide cfDNA screen-
ing compared with standard cfDNA screening (Ehrich et al., 2017). 
While screening for microdeletion syndromes, single- gene disor-
ders, and autosomal aneuploidies other than common aneuploidies 
is not currently recommended by ACOG/ACMG/SMFM due to lack 
of clinical validation studies, it could be considered in the setting of a 
fetus with a congenital anomaly when diagnostic testing is declined 
and with appropriate counseling on limitations.
Overall, amniocentesis with CMA should be offered to all families 
of a fetus with a CHD, regardless of screening results or presence/
absence of additional sonographic findings. If amniocentesis is de-
clined, postnatal CMA on cord blood should be considered. Genetic 
counselors should note whether the testing laboratory utilizes a dif-
ferent platform or different reporting criteria in prenatal vs. postna-
tal samples. From a cost- saving perspective, if available, reanalysis 
of the prenatal data may be preferred to repeat postnatal analysis.
The presence of additional family members with congenital 
anomalies or developmental delays or a family history of recurrent 
pregnancy loss, stillbirth/infant death or infertility may be sugges-
tive of an underlying chromosome abnormality or genetic syndrome 
in the family, perhaps with recurrence in the fetus. In cases where 
the etiology remains elusive, affected relatives may consider a ge-
netics evaluation. If counseling a couple with a history of recurrent 
miscarriage, parental chromosome analysis would be indicated and 
may help to uncover the cause of the CHD in the fetus.
In the setting of a perinatal loss, autopsy should be offered 
to evaluate for additional abnormalities, such as CHD, which 
may suggest an etiology. ACOG recommends a CMA be consid-
ered (Committee on Genetics and the Society for Maternal- Fetal 
Medicine). Additionally, in some instances, ES may want to be con-
sidered following an inconclusive CMA result.
Recurrence risk counseling for subsequent pregnancies follow-
ing the prenatal diagnosis of a fetal CHD should be approached with 
caution unless a specific genetic diagnosis is made. Accurate risk as-
sessment is challenging since the specific lesion can be difficult to 
characterize prenatally and it is not possible to be certain a CHD is 
truly isolated. See below for psychosocial considerations for prena-
tal genetic counseling.
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10  | PSYCHOSOCIAL CONSIDER ATIONS
Literature suggests that parents of a child with CHDs suffer from 
increased levels of hopelessness and distress, including anxiety 
and depression when compared with parents of healthy controls 
and importantly when compared to parents of children with other 
diseases (Blue et al., 2015; Grønning Dale et al., 2013; Lawoko & 
Soares, 2002, 2006). Additionally, families of children with more 
severe cardiac defects have shown more significant impact on so-
cial relationships, financial burden, personal strain, and challenges 
with siblings compared with families with milder CHDs (Almesned 
et al., 2013; Brosig et al., 2007; Connor et al., 2010).
Genetic counselors are uniquely posed to provide not only in-
formation to these patients and families, but psychosocial support 
as well. Studies have found that families who pursued genetic coun-
seling reported increases in knowledge and decreases in depression, 
anxiety, and stress (Blue et al., 2015).
The questions of ‘why’ and ‘how’ a CHD occurs are at the 
forefront of the minds of parents of children with CHD. Receiving 
information related to the etiology of CHD through genetic coun-
seling sessions results in increased personal control and decreased 
reports of guilt, depression, anxiety, and stress (Blue et al., 2015). 
Important considerations related to the timing, delivery, and type of 
information pertaining to genetic factors in CHDs have been stud-
ied. A significant number of parents (87%) report genetic factors 
as quite or extremely important; however, in the same study, only 
36% recalled receiving such information (Kasparian et al., 2014). In 
another study related to genetic counseling services for parents of 
children with CHD, parents reported high satisfaction (96%) with 
genetic counseling services and would recommend genetic coun-
seling sessions to other parents. Nearly all parents surveyed (98%) 
in one study reported information on recurrence risks of CHD is 
important, though only 7% recalled receiving this information from 
a healthcare provider (Blue et al., 2015). Evaluation of when and 
how families prefer to receive information related to the genetic 
factors of CHD shows a preference for a single appointment, with 
the presence of a clinical geneticist and genetic counselor, spoken 
and web- based information, and availability of the information 
within two weeks (Kasparian et al., 2018). Collectively, this work 
underscores the importance of including genetic counseling related 
to CHDs in the multidisciplinary care of these families. We encour-
age our community to continue to seek to understand, and publish 
findings related to, patient perception of CHD genetic counseling.
10.1 | Unique psychosocial considerations for 
prenatal genetic counseling
Genetic counseling in the setting of a fetal CHD is complex for the 
reasons outlined above. In addition, there are unique psychosocial 
issues. At the time of counseling, families are often struggling to 
come to terms with their unborn baby having significant medical 
needs and the genetic counselor may be the first person to discuss 
the possibility the fetal CHD may not be ‘isolated’ even though it 
appears to be on prenatal ultrasound. Families are typically over-
whelmed at the time of counseling, as the diagnosis may be recent, 
they may be learning about additional prenatal findings and they 
may need to deliver the baby far from home.
Discussion of the potential for an underlying genetic cause with as-
sociated developmental/medical concerns and/or a shortened lifespan 
can be especially difficult during pregnancy when they have yet to ‘meet’ 
their baby. The pervasive uncertainty surrounding the exact nature of 
the CHD, underlying diagnosis, and potential prognosis in the prena-
tal setting can be especially difficult for families to manage. In addition, 
some families may consider termination of pregnancy or compassionate 
postnatal care. Decisions regarding termination of pregnancy can be 
challenging since a CHD is typically not diagnosed until late in the sec-
ond trimester and results from genetic testing may take several weeks.
During contracting, it is helpful to assess what the family under-
stands about the fetal CHD and how they are coping with the diag-
nosis. It is also helpful to inquire about their support system and to 
provide contacts for local resources as appropriate (e.g., perinatal 
bereavement, palliative care, First Steps, and support groups).
Prenatal genetic counseling in the setting of a fetal CHD is com-
plex, but essential. It prepares families for the possibility of addi-
tional noncardiac abnormalities. It also helps families understand the 
importance of genetic testing/evaluation to provide the best care 
for their baby and to provide accurate recurrence risk counseling for 
subsequent pregnancies.
11  | DISCUSSION & FUTURE 
PERSPEC TIVES
The purpose of this practice resource is to serve as a foundation 
for genetic counselors approaching CHDs in their work, regardless 
of their underlying specialty. Despite being the most common birth 
defect in humans, genetic counseling approaches to CHDs can be 
complex because of the significant biological and genetic complex-
ity, diversity of testing options, clinical indications, and varying prac-
tice models involving multidisciplinary teams of genetic counselors, 
medical geneticists, and cardiologists or other specialists. We en-
courage readers to refer to Table 5 for an outline of key considera-
tions from each section of this manuscript.
We expect that the field will move more toward ES/GS as first- 
tier testing strategies for patients with CHDs, and this will lead to 
even greater need for genetic professionals well versed in the com-
plexity of counseling in CHD settings and interpretation, manage-
ment and counseling of CHD genetic testing results. Genomic- scale 
testing strategies have the capability to generate more information 
than can be meaningfully interpreted for clinical utility, and this will 
require multidisciplinary clinical teams that complement their re-
spective domains of expertise. We encourage genetic counselors 
to contribute to research in this area, especially with the possible 
development of polygenic models of disease that incorporate di-
verse genomic variation across hundreds of genes involved in the 
     |  19ISON et al.
TA B L E  5   Summary of recommendations for CHD Counseling in practice
Targeted family history assessment for CHD
• When possible, a four- generation pedigree should be obtained to provide a broad overview of the family history and assist with guiding the 
suspected etiology (environmental, monogenic, cytogenetic (microdeletion/duplication, aneuploidy, and/or structural rearrangements), or 
multifactorial/complex.
• It is recommended that the following information be obtained when assessing the family history:
• Are there any other family members with congenital heart disease and/or congenital anomalies?
• If yes, does the individual appear to have isolated or syndromic disease (dysmorphic features, intellectual disability, developmental delay, 
autism, etc.)? Have they undergone genetic testing? If so, is the family aware of the result and/or have the ability to obtain additional 
information on this history?
• If there is a family history of CHD(s), do the CHDs appear to fall within the same Botto class (potentially indicating a similar underlying 
genetic etiology) or separate?
• Is there a family history of recurrent miscarriages, infertility, stillbirths, or infantile death indicative of chromosomal structural 
rearrangements or severe syndromes?
• Is there a family history of arrhythmias, pacemakers/implanted defibrillators, or sudden cardiac death? This question can assess for CHD 
genes which may present with arrhythmias/conduction disease (e.g., NKX2.5, TBX5, etc.).
• Given that CHDs can occur due to autosomal recessive inheritance, it is important to assess for consanguinity. Ancestry is less likely to assist 
with gene/disease differentials, but this may change as our understanding of the etiology of CHD(s) evolve. CHDs occur across all global 
geographic regions.
• It is important to keep in mind that due to reduced penetrance and variable expressivity, it is not always possible to determine if a CHD is truly 
isolated and/or sporadic in a proband and/or the family.
Genetic testing for CHD
• Based on current research, CMA has the highest diagnostic yield and has been shown to be cost- effective for both syndromic and 
nonsyndromic CHDs. Because of this, it should be considered a first- tier test to consider for those with CHDs.
• Those with syndromic presentations (e.g., extracardiac anomalies, developmental delay, etc.) should ideally be evaluated by a medical geneticist 
and other testing options may be prioritized (e.g., syndrome- specific genetic testing).
• At present, the diagnostic yield and clinical utility for CMA testing in adult CHD patients requires further exploration (especially for apparently 
isolated CHDs).
• Multigene panels for CHDs (both syndromic and non- syndromic) can be useful and likely cost- effective. However, studies are limited in 
demonstrating diagnostic yields for apparently isolated CHDs (familial and sporadic). Further research is required to determine diagnostic yield 
in different CHD cohorts: syndromic, apparently isolated, sporadic, and familial.
Genetic counseling for CHD recurrence risk
• If a pathogenic monogenic cause of isolated CHD is identified, a thorough assessment of the variant and data supporting its 
pathogenicity should be reviewed, and reduced penetrance and variable expressivity should be emphasized to patients/families when 
appropriate.
• If a potential monogenic cause of familial isolated CHD is identified (i.e., a variant of uncertain significance), and there is evidence suggesting its 
possible involvement in the familial cardiac disease, segregation testing can be considered for affected family members. Patients should receive 
careful counseling around the likelihood of the variant being reclassified based on this data, as well as the potential for the variant to remain 
a VUS despite segregation studies. Patients/families should be encouraged to check in with their team every few years to learn if there are 
updates to the classification of any uncertain variants detected.
• In the absence of a genetic etiology, empiric risks can be used as a baseline and modified based on other factors such as family history of CHDs 
or known teratogenic or environmental exposures (Figure 3). However, it should be made clear to families that this is only an estimate based on 
our current understanding of empiric risks and the patient’s and family’s histories. A family’s true risk may be higher or lower than the estimate 
and based on population data and other risk factors present.
CHD family screening recommendations
• At this time, screening echocardiograms for first- degree relatives of an individual with an isolated LVOTO (like bicuspid aortic 
valve, aortic stenosis, coarctation of the aorta, mitral atresia, and hypoplastic left heart) has been specifically recommended in the 
literature.
• For non- LVOTO class of CHDs, family screening recommendations may depend on whether or not there is familial disease as well as parental 
concerns about recurrence risk in future pregnancies.
• When a causative genetic variant is identified, family screening can generally follow cascade genetic testing for individuals who inherited 
the variant. For some CHD genes that can present with risk of arrhythmia/cardiomyopathy, a single echocardiogram to exclude cardiac 
malformations may not suffice; long- term surveillance may still be recommended for these other cardiac manifestations.
CHD and a multidisciplinary approach
• It is recommended that genetic counselors interested in working with the CHD population assess their institutional dynamics and provider/
specialist availability. Each institution will have unique contexts and different referral patterns requiring flexible approaches; close 
collaboration between genetics providers and the CHD care team is essential for both pediatric and adult CHD programs.
(Continues)
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complex interplay between cardiac developmental genes. As a for-
mal Practice Resource, this will undergo periodic re- review accord-
ing to the NSGC Practice Guidelines policy. Continuously improving 
genomic diagnostic testing and knowledge of the genetic architec-
ture of CHDs will likely lead to changes in genetic counseling strate-
gies for the CHD population in the future.
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Considerations for prenatal genetic counseling
• It is important to assess for the following prenatal history: dosage and timing of any maternal medication exposure, maternal A1c levels, level 
of gestational or pre- gestational diabetes control in mothers with diabetes, and the timing and diagnosis (if known) of any maternal illness and/
or exposures to teratogens. This infomration should also be collected if seeing a patient postnatally in order to assess for potential secondary 
causes of the CHD.
• Fetal echo should be considered pursuant to Table 4.
• A woman with a personal history of CHD should be referred to both perinatology and cardiology specialists with expertise in caring for such 
high- risk pregnancies.
• If a CHD is diagnosed prenatally, the fetus should be carefully evaluated for the presence of additional extracardiac anomalies.
• Amniocentesis with chromosomal microarray analysis should be offered when a fetus is diagnosed with a CHD; if amniocentesis is declined, 
screening for chromosome abnormalities through cell free DNA testing should be offered.
• If amniocentesis is declined, CMA on cord blood should be considered.
• Newborns with prenatally diagnosed CHDs would benefit from evaluation by a medical geneticist familiar with cardiovascular conditions or 
cardiologist with expertise in genetics.
• Families should be counseled that a diagnosis may change after delivery and appropriate follow- up with a pediatric cardiologist is 
recommended for postnatal evaluation
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